Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia

NCT06658899 is registered in ClinicalTrials.gov with Cardurion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06658899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06658899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
December 1, 2025
Completion date
April 30, 2027
Enrollment
12 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

catecholaminergic polymorphic ventricular tachycardia